GlycoMimetics Phase 3 uproleselan misses primary OS endpoint; positive subgroup in primary refractory AML

CRESCENT BIOPHARMA, INC.

Phase 3 missed primary endpoint: mOS 13.0 vs 12.3 months (HR 0.89; 95% CI 0.69-1.15), not statistically significant.
In primary refractory AML (n=128), mOS improved to 31.2 vs 10.1 months (HR 0.58; 95% CI 0.37-0.91).
Safety consistent with chemotherapy; no new adverse event signals.
Company planning to engage regulators and NCI; Phase 2/3 study in frontline AML advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.